nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

18.06.2019 | Original Article

Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients

verfasst von: Kimihiko Goto, Shunsuke Goto, Hideki Fujii, Kentaro Watanabe, Keiji Kono, Shinichi Nishi

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Recent clinical studies demonstrated the favorable effects of calcium-free phosphate binders on mortality and vascular calcification in hemodialysis (HD) patients. The aim of the present study was to investigate the effects of a calcium-free phosphate binder, lanthanum carbonate (LC), on bone metabolic markers and bone mineral density (BMD), compared with those of calcium carbonate (CC), in subjects new to HD.

Materials and Methods

The present study included 65 subjects from our previous randomized controlled trial (LC group, N = 31; CC group, N = 34). We investigated the effects of LC on serum intact parathyroid hormone (iPTH), osteocalcin (OC), bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRACP-5b), sclerostin levels, and BMD, compared with those of CC in patients new to HD at baseline and at 12 and 18 months.

Results

Serum OC levels at 18 months were significantly higher in the LC group than in the CC group. During the study period, serum BAP and TRACP-5b and iPTH levels tended to be higher in the LC group than in the CC group. At 18 months, the percentage of low bone turnover, based on a serum BAP cutoff value, was significantly lower in the LC group than in the CC group. There were no significant differences in the lumbar and femoral BMD between the two groups.

Conclusions

The results of the present study suggest that LC has potential in preventing low bone turnover, in comparison to CC, in patients new to HD.

Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731CrossRef

Wakasugi M, Kazama JJ, Taniguchi M et al (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321CrossRef

Tentori F, McCullough K, Kilpatrick RD et al (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166–173CrossRef

Young EW, Albert JM, Satayathum S et al (2005) Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 67:1179–1187CrossRef

Jamal SA, Vandermeer B, Raggi P et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:1268–1277CrossRef

Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) guideline update: what’s changed and why it matters. Kidney Int 92:26–36CrossRef

Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S (2018) Effects of lanthanum carbonate on coronary artery calcification and cardiac abnormalities after initiating hemodialysis. Calcif Tissue Int 102:310–320CrossRef

Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology 16:290–298CrossRef

D’Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 85:S73–S78CrossRef

10.

Malluche HH, Siami GA, Swanepoel C et al (2008) Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70:284–295PubMed

11.

Inaba M, Okuno S, Nagayama H et al (2015) Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr 25:242–246CrossRef

12.

Wada K, Wada Y, Uchida HA, Tsuruoka S (2015) Effects of lanthanum carbonate versus calcium carbonate on vascular stiffness and bone mineral metabolism in hemodialysis patients with type 2 diabetes mellitus: a randomized controlled trial. Int J Nephrol Renov Dis 8:111–118CrossRef

13.

Zhang C, Wang S, Zhao S, Zhang X (2017) Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: a prospective pilot study. Med (Baltim) 96:e8664CrossRef

14.

Soohoo M, Feng M, Obi Y et al (2016) Changes in markers of mineral and bone disorders and mortality in incident hemodialysis patients. Am J Nephrol 43:85–96CrossRef

15.

Fukagawa M, Yokoyama K, Koiwa F et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247–288CrossRef

16.

Coen G, Ballanti P, Bonucci E et al (1998) Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 13:2294–2302CrossRef

17.

Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R (2018) Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29:1557–1565CrossRef

18.

World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

19.

Nishizawa Y, Ohta H, Miura M et al (2013) Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1–15CrossRef

20.

London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943–1951CrossRef

21.

Barreto DV, Barreto FC, Carvalho AB et al (2008) Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 52:1139–1150CrossRef

22.

Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC (1996) Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7:506–512PubMed

23.

Fusaro M, Giannini S, Gallieni M et al (2016) Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. Endocrine 51:333–341CrossRef

24.

Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150PubMed

25.

Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287–293CrossRef

26.

Iimori S, Mori Y, Akita W et al (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study. Nephrol Dial Transplant 27:345–351CrossRef

27.

Zhai CJ, Yang XW, Sun J, Wang R (2015) Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systemic review and meta-analysis. Int Uro Nephrol 47:527–535CrossRef

28.

Harini D, Indra R, Rajaram A, Rajaram R (2014) Induction of osteoblast differentiation in human adipose derived stem cells by lanthanum ions. J Rare Earths 32:1080–1088CrossRef

29.

Wang X, Yuan L, Huang J, Zhang TL, Wang K (2008) Lanthanum enhances in vitro osteoblast differentiation via pertussis toxin-sensitive gi protein and ERK signaling pathway. J Cell Biochem 105:1307–1315CrossRef

30.

Fumoto T, Masako I, Kyoji I (2014) Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover. J Bone Miner Metab 32:484–493CrossRef

31.

Sabbagh Y, Graciolli FG, O’Brien S et al (2012) Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27:1757–1772CrossRef

32.

Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29–37CrossRef

33.

Seifert ME, de las Fuentes L, Rothstein M et al (2013) Effects of phosphate binder therapy on vascular stiffness in early stage chronic kidney disease. Am J Nephrol 38:158–167CrossRef

Titel: Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients
verfasst von: Kimihiko Goto
Shunsuke Goto
Hideki Fujii
Kentaro Watanabe
Keiji Kono
Shinichi Nishi
Publikationsdatum: 18.06.2019
Verlag: Springer Japan
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 6/2019
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-019-01018-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients

Abstract

Introduction

Materials and Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Blasenkarzinom – Biomarker statt Zytologie?

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women

Prevalence and co-existence of locomotive syndrome, sarcopenia, and frailty: the third survey of Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study

Systematic and meta-analytic analysis of cross-sectional and longitudinal explorations of bone health in youth with obesity: from methodological considerations to clinical relevance

The age modification to leukocyte telomere length effect on bone mineral density and osteoporosis among Chinese elderly women

Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation

Retraction Note To: The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density: a systematic review and meta-analysis of cohort studies

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Blasenkarzinom – Biomarker statt Zytologie?

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin